

ASX Announcement

20 August 2025

FY 25 Annual Results & Investor Webinar

Genetic Signatures [ASX:GSS] (“**GSS**” or “**the Company**”), a global molecular diagnostics company, will release its FY 25 annual results on Monday, 25 August 2025.

To accompany the release, the Company will host an investor webinar at 11am (AEST) where Chief Executive Officer, Allison Rossiter and Chief Financial Officer, Karl Pechmann will present the results and address investor questions.

To register for the session and submit your questions in advance, please visit this link:

https://us06web.zoom.us/webinar/register/WN_Q0rq0f_-THeiO_lqc9Cg2w

– END –

Announcement authorised by the Chief Executive Officer

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.